Compare Globus Medical Inc. Class A Common Stock (GMED) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.86 (market cap $17.70B). The key difference: iShares Broad USD Investment Grade Corporate Bond is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and iShares Broad USD Investment Grade Corporate Bond for 46 Days on average.
| GMED | USIG | |
|---|---|---|
Market Cap | $10.25B | $17.70B |
Volume | 1,108,124 | 2,181,370 |
Sector | Health | Fixed Income |
52-Week High | $96.82 | $52.69 |
52-Week Low | $58.33 | $48.54 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
USIG trades at $48.84 with minimal daily movement (+0.03%). Technical indicators show a bearish bias with moving averages signaling selling pressure, though oscillators remain neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The ETF maintains regular dividend distributions, with recent payments of $0.20-0.21 per share.
The investment grade corporate bond ETF faces headwinds from rising interest rate concerns, though institutional accumulation suggests confidence in its credit quality. Key risks include bond market volatility and credit spread fluctuations. Current technical weakness warrants caution despite the neutral sentiment from oscillators and institutional buying interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
